Clinical Trial Update: Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL [Phase 2]

View source ↗

Summary

Phase 2 study evaluating sequencing of Blinatumomab, Venetoclax, and Inotuzumab Ozogamicin for B-cell acute lymphoblastic leukemia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• BLINCYTO (BLINATUMOMAB)
• Besponsa (inotuzumab ozogamicin)
• Venclexta (venetoclax)

Snippet

Sponsor: First Affiliated Hospital of Zhejiang University | Conditions: Precursor B-Cell Lymphoblastic Leukemia | Phase 2 | Status: RECRUITING